Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2- and TET2-mutant acute myeloid leukemia

Genomic studies in acute myeloid leukemias (AML) have identified mutations which drive altered DNA methylation, including TET2 and IDH2. Here we show that models of AMLs resulting from TET2 or IDH2 mutations combined with FLT3(ITD) mutations are sensitive to 5-Azacytidine or to the IDH2 inhibitor AG...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Shih, Alan H, Meydan, Cem, Shank, Kaitlyn, Garrett-Bakelman, Francine E, Ward, Patrick S, Intlekofer, Andrew, Nazir, Abbas, Stein, Eytan, Knapp, Kristina, Glass, Jacob, Travins, Jeremy, Straley, Kim, Gliser, Camelia, Mason, Chris, Yen, Katharine, Thompson, Craig B, Melnick, Ari, Levine, Ross L
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5413413/
https://ncbi.nlm.nih.gov/pubmed/28193779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1049
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados